Abstract

Objectives: In 1997, a study was launched to investigate the treatment of early prostate cancer. Using a patient preference design, health-related quality-of-life (HRQOL) and disease specific HRQOL was assessed prospectively to compare men undergoing radical prostatectomy (RP), hypo-fractionated conformal radiotherapy (CRT) or brachytherapy (BT). Methods: Patients with localised prostate cancer were counselled by a urological surgeon, clinical oncologist and specialist uro-oncology nurse. Patients received treatment according to individual preference. 430 men chose and received RP (n = 217), CRT (n = 161) and BT (n = 52). 354 (82%) completed pre-treatment RAND 36-Item Short-Form Health survey version-2 (SF36v2) and University of California, Los Angeles Prostate cancer index (UCLA-PCI) questionnaires. HRQOL score changes from baseline to 24 months were compared using Kruskall-Wallis test. Results: Pre-treatment, the CRT cohort scored lower for physical function (p = 0.0029) and general health perception (p = 0.0021). The BT cohort reported better baseline scores for urinary function (p = 0.0291), urinary bother (p = 0.0030), sexual function (p = 0.0009) and bowel bother (p = 0.0063). At 24 months, bowel function was similar for CRT and BT but both modalities were worse than RP (p = 0.0010). Urinary continence deteriorated most following RP (p < 0.0001) but BT had worse urinary bother (p = 0.0153). Sexual function deteriorated most following RP and BT (p < 0.0005). Percentages of patients achieving erections adequate for sexual activity (from baseline to 24 months) were 66% to 29% for RP, 62% to 49% for CRT and 88% to 65% for BT. Conclusion: This data demonstrates significant differences in disease specific quality-of-life between RP, CRT and BT and should be available for men with early prostate cancer making treatment decisions.

Highlights

  • Men undergoing treatment for early prostate cancer are faced with a decision about which therapeutic option to choose

  • At 24 months, bowel function was similar for conformal radiotherapy (CRT) and BT but both modalities were worse than radical prostatectomy (RP) (p = 0.0010)

  • Between 1st December 1997 and 1st April 2004, 490 men registered in the quality of life aspect of the study

Read more

Summary

Introduction

Men undergoing treatment for early prostate cancer are faced with a decision about which therapeutic option to choose. This is due to the increasing number of available treatments, each with differing side effects. Patients make their decisions following advice from their specialist, which may be biased towards the treatment they offer [1]. PSA testing and screening programmes have changed the profile of prostate cancer, increasing the proportion of patients with early disease at low risk of becoming symptomatic. In this group of patients, with long life. Quality of life after primary definitive treatment is an important outcome as many would contemplate reduction in life expectancy for treatments with fewer side effects [2,3]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call